Literature DB >> 31894500

Synergistic Effects of Efflux Pump Modulators on the Azole Antifungal Susceptibility of Microsporum canis.

Chioma Inyang Aneke1,2, Wafa Rhimi1,3, Domenico Otranto1, Claudia Cafarchia4.   

Abstract

The microbiologic and clinical resistance of dermatophytes is seldom reported, and the mechanisms associated with resistance are not well known. This study investigated the effect of efflux pump modulators (EPMs) (i.e., haloperidol HAL and promethazine PTZ) and their inhibiting activity on the minimum inhibitory concentrations of itraconazole (ITZ) and fluconazole (FLZ) against selected M. canis strains. M. canis strains with low (≤ 1 μg/ml itraconazole and < 64 μg/ml fluconazole) and high (> 1 μg/ml itraconazole and ≥ 64 μg/ml fluconazole) azole MIC values were tested using Checkerboard microdilution assay. The disk diffusion assay, the minimum fungicidal concentration and the time-kill assay were also performed in order to confirm the results of checkerboard microdilution assay. The MIC values of ITZ and FLZ of M. canis decreased in the presence of subinhibitory concentrations of HAL and PTZ, the latter being more effective with a greater increased susceptibility. Synergism was observed in all strains with high azole MICs (FICI < 0.5) and no synergism in the strains with low azole MICs. A fungicidal activity was observed after 48 h of incubation when ITZ and FLZ were tested in combination with HAL or PTZ. These results suggest that the drug efflux pumps are involved in the defense mechanisms to azole drugs in M. canis strains. The synergism might be related to an increased expression of efflux pump genes, eventually resulting in azole resistance phenomena. Complementary studies on M. canis resistance are advocated in order to investigate the molecular mechanisms of this phenomenon.

Entities:  

Keywords:  Azole resistance; Efflux pump; Microsporum canis; Minimum inhibitory concentrations.; Synergism

Year:  2020        PMID: 31894500     DOI: 10.1007/s11046-019-00419-7

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  38 in total

1.  Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole.

Authors:  Javier Afeltra; Roxana G Vitale; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Molecular characterization of selected dermatophytes and their identification by electrophoretic mutation scanning.

Authors:  Claudia Cafarchia; Domenico Otranto; Stefania Weigl; Bronwyn E Campbell; Antonio Parisi; Cinzia Cantacessi; Francesca Mancianti; Patrizia Danesi; Robin B Gasser
Journal:  Electrophoresis       Date:  2009-10       Impact factor: 3.535

3.  Cyclosporine A decreases the fluconazole minimum inhibitory concentration of Candida albicans clinical isolates but not biofilm formation and cell growth.

Authors:  T Wibawa; I Baly; P R Daeli; G Kartasasmita; N Wijayanti
Journal:  Trop Biomed       Date:  2015-03       Impact factor: 0.623

4.  Phenothiazines as potent modulators of yeast multidrug resistance.

Authors:  Marcin Kolaczkowski; Krystyna Michalak; Noboru Motohashi
Journal:  Int J Antimicrob Agents       Date:  2003-09       Impact factor: 5.283

Review 5.  Efflux-mediated antifungal drug resistance.

Authors:  Richard D Cannon; Erwin Lamping; Ann R Holmes; Kyoko Niimi; Philippe V Baret; Mikhail V Keniya; Koichi Tanabe; Masakazu Niimi; Andre Goffeau; Brian C Monk
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

6.  Yeast microbiota of raptors: a possible tool for environmental monitoring.

Authors:  Raimunda S N Brilhante; Débora S C M Castelo Branco; Guilherme P S Duarte; Manoel A N Paiva; Carlos E C Teixeira; João P O Zeferino; André J Monteiro; Rossana A Cordeiro; José J C Sidrim; Marcos F G Rocha
Journal:  Environ Microbiol Rep       Date:  2012-01-04       Impact factor: 3.541

7.  Antimycotic effectiveness against dermatophytes: comparison of two in vitro tests.

Authors:  Roberta Galuppi; Alessandra Gambarara; Cristina Bonoli; Fabio Ostanello; Maria Paola Tampieri
Journal:  Vet Res Commun       Date:  2010-06       Impact factor: 2.459

8.  In vitro antifungal drug susceptibilities of dermatophytes microconidia and arthroconidia.

Authors:  Luciene M Coelho; Roseli Aquino-Ferreira; Cláudia M Leite Maffei; Nilce M Martinez-Rossi
Journal:  J Antimicrob Chemother       Date:  2008-06-13       Impact factor: 5.790

9.  Resistance Mechanism in a Terbinafine-Resistant Strain of Microsporum canis.

Authors:  Rui Kano; Yun-Hsia Hsiao; Hock Siew Han; Charles Chen; Atsuhiko Hasegawa; Hiroshi Kamata
Journal:  Mycopathologia       Date:  2018-01-16       Impact factor: 2.574

10.  Toward a Novel Multilocus Phylogenetic Taxonomy for the Dermatophytes.

Authors:  G Sybren de Hoog; Karolina Dukik; Michel Monod; Ann Packeu; Dirk Stubbe; Marijke Hendrickx; Christiane Kupsch; J Benjamin Stielow; Joanna Freeke; Markus Göker; Ali Rezaei-Matehkolaei; Hossein Mirhendi; Yvonne Gräser
Journal:  Mycopathologia       Date:  2016-10-25       Impact factor: 2.574

View more
  5 in total

Review 1.  Reassessing the Use of Undecanoic Acid as a Therapeutic Strategy for Treating Fungal Infections.

Authors:  Antonio Rossi; Maíra P Martins; Tamires A Bitencourt; Nalu T A Peres; Carlos H L Rocha; Flaviane M G Rocha; João Neves-da-Rocha; Marcos E R Lopes; Pablo R Sanches; Júlio C Bortolossi; Nilce M Martinez-Rossi
Journal:  Mycopathologia       Date:  2021-04-09       Impact factor: 2.574

Review 2.  Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.

Authors:  Anne-Laure Bidaud; Patrick Schwarz; Guillaume Herbreteau; Eric Dannaoui
Journal:  J Fungi (Basel)       Date:  2021-02-04

Review 3.  Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.

Authors:  Aidan Kane; Dee A Carter
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-14

Review 4.  Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.

Authors:  Thomas R Rogers; Paul E Verweij; Mariana Castanheira; Eric Dannaoui; P Lewis White; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2022-07-28       Impact factor: 5.758

5.  Virulence and Antifungal Susceptibility of Microsporum canis Strains from Animals and Humans.

Authors:  Chioma Inyang Aneke; Wafa Rhimi; Vit Hubka; Domenico Otranto; Claudia Cafarchia
Journal:  Antibiotics (Basel)       Date:  2021-03-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.